---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-009480"
form_type: "8-K"
ticker: "PEPG"
cik: "0001835597"
company_name: "PepGen Inc."
filed_at: "2023-03-23T23:59:59+00:00"
generated_at: "2026-06-17T19:15:41.104616+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PepGen FY2022 net loss $69.1M, cash $181.8M; Phase 2 trials planned for 2023

## Summary
- Net loss $14.9M in Q4 2022, $69.1M for full year 2022 (vs $27.3M in 2021).
- Cash and cash equivalents $181.8M as of Dec 31, 2022; expected to fund operations into early 2025.
- R&D expenses $54.1M in FY2022 (vs $19.0M in 2021) driven by PGN-EDO51 and PGN-EDODM1 programs.
- Anticipates initiating CONNECT1-EDO51 (Phase 2 open-label) in H1 2023 and CONNECT2-EDO51 (randomized) in H2 2023.
- Phase 1 FREEDOM-DM1 trial for myotonic dystrophy type 1 expected to start H1 2023.

## SEC filing metadata
- accession: 0000950170-23-009480
- form_type: 8-K
- ticker: PEPG
- cik: 0001835597
- company_name: PepGen Inc.
- filed_at: 2023-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835597/000095017023009480/0000950170-23-009480-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835597/000095017023009480/pepg-20230323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-009480
- JSON: https://secwatch.observer/filing/0000950170-23-009480.json
- Plain text: https://secwatch.observer/filing/0000950170-23-009480.txt

## Key facts
- Earnings Releases
  PepGen Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Result: reported results
  source text: PepGen Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Developments
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835597/000095017023009480/0000950170-23-009480-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.